13F Holdings
中文EN

NNNN Anbio Biotechnology Annual reports only

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1982708 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY5.6%
TTM net income YoY169.9%
TTM EPS YoY162.5%
Revenue 3-yr CAGR-28.4%
Net income 3-yr CAGR-13.8%

Margins

Gross margin87.2%
Operating margin66.7%
Net margin74.1%
FCF margin—
EBITDA margin—

Returns

ROE27.0%
ROA26.0%
ROIC (approx.)41.5%
Asset turnover0.35x

Leverage & solvency

Liabilities / assets0.3%
Debt / equity0.00x
Current ratio344.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.05x
Accruals ratio53.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$8.65M$8.19M$6.71M$23.54M
Cost of revenue$1.10M$2.30M$3.35M$10.98M
Gross profit$7.54M$5.89M$3.36M$12.56M
R&D expense$201,305$454,227$134,700$200,000
SG&A expense$1.57M$3.44M$1.27M$2.17M
Operating income$5.77M$2.00M$1.96M$10.20M
Interest expense———$7,999
Pretax income$6.40M$2.37M$2.25M$10.01M
Income tax$0$0$0—
Net income$6.40M$2.37M$2.25M$10.01M
EPS (basic)0.150.060.10100,112.00
EPS (diluted)0.150.060.10100,112.00
Weighted avg. shares (diluted)43.67M42.29M21.44M—
Balance sheet
Cash & equivalents$7.77M$11.76M$9.69M$7.10M
Short-term investments$4.13M$0——
Receivables$3.66M$1.06M$1.88M—
Current assets$30.24M$18.53M$15.75M—
Total assets$30.24M$18.92M$15.81M—
Current liabilities$87,836$1.73M$993,060—
Total liabilities$87,836$1.73M$993,060—
Shareholders' equity$30.16M$17.19M$14.82M$12.55M
Cash flow statement
Operating cash flow-$6.74M$2.08M$898,367$4.45M
Investing cash flow-$4.20M$337,101$1.73M-$1.53M
Financing cash flow$6.95M-$344,605-$42,835—

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.